89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
A phase 3 trial of CAIX PET in Clear cell renal cell carcinoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, completed.
Overview
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study is a phase 3 interventional study registered as NCT03849118 by Telix Pharmaceuticals (Innovations) Pty Limited, with 300 participants recorded, started 2019-08-15 and reaching its primary completion in 2022-10-20. Interventions recorded: 89Zr-girentuximab. Conditions recorded: Clear Cell Renal Cell Carcinoma.
Linked to the technology CAIX PET because the registry names it ("89zr girentuximab") among its interventions and Clear cell renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialAn Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Shares CAIX PET (89Zr-girentuximab), Clear cell renal cell carcinoma and the tag pipeline.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Clear cell renal cell carcinoma and the tag pipeline.
- TrialAB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Shares Clear cell renal cell carcinoma and the tag pipeline.
- TrialPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Shares Clear cell renal cell carcinoma and the tag pipeline.
- TrialA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Shares Clear cell renal cell carcinoma and the tag pipeline.
- Trial89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Shares CAIX PET (89Zr-girentuximab), Clear cell renal cell carcinoma.
- TargetHIF-2α
Shares CAIX PET (89Zr-girentuximab), Clear cell renal cell carcinoma.